Vanda Pharmaceuticals reports positive Phase 3 results for HETLIOZ in delayed sleep-wake phase disorder

Vanda Pharmaceuticals announced positive Phase 3 results for HETLIOZ (tasimelteon) in delayed sleep-wake phase disorder. The study met its primary endpoint, with sleep onset timing shifting 37.1 minutes earlier versus placebo (p=0.022).

Detected & updated continuously · Source: Nebula